GB1385086A - Insulin product - Google Patents
Insulin productInfo
- Publication number
- GB1385086A GB1385086A GB1974172A GB1974172A GB1385086A GB 1385086 A GB1385086 A GB 1385086A GB 1974172 A GB1974172 A GB 1974172A GB 1974172 A GB1974172 A GB 1974172A GB 1385086 A GB1385086 A GB 1385086A
- Authority
- GB
- United Kingdom
- Prior art keywords
- insulin
- alkali metal
- protamine
- salt
- aqueous medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 17
- 102000004877 Insulin Human genes 0.000 title abstract 8
- 108090001061 Insulin Proteins 0.000 title abstract 8
- 229940125396 insulin Drugs 0.000 title abstract 8
- 229940048914 protamine Drugs 0.000 abstract 4
- 102000007327 Protamines Human genes 0.000 abstract 3
- 108010007568 Protamines Proteins 0.000 abstract 3
- 229910052783 alkali metal Inorganic materials 0.000 abstract 3
- 239000012736 aqueous medium Substances 0.000 abstract 3
- 150000001340 alkali metals Chemical class 0.000 abstract 2
- 150000003863 ammonium salts Chemical class 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 abstract 1
- 229910001413 alkali metal ion Inorganic materials 0.000 abstract 1
- -1 alkali metal salt Chemical class 0.000 abstract 1
- 229910052792 caesium Inorganic materials 0.000 abstract 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 239000000644 isotonic solution Substances 0.000 abstract 1
- 229910052744 lithium Inorganic materials 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13912071A | 1971-04-30 | 1971-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1385086A true GB1385086A (en) | 1975-02-26 |
Family
ID=22485216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1974172A Expired GB1385086A (en) | 1971-04-30 | 1972-04-28 | Insulin product |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US3758683A (enExample) |
| JP (1) | JPS5735185B1 (enExample) |
| BE (1) | BE782651A (enExample) |
| CA (1) | CA976085A (enExample) |
| CH (1) | CH566784A5 (enExample) |
| CS (1) | CS209458B2 (enExample) |
| DD (1) | DD100708A5 (enExample) |
| DE (1) | DE2219635C3 (enExample) |
| DK (1) | DK131760C (enExample) |
| ES (1) | ES402176A1 (enExample) |
| FI (1) | FI49773C (enExample) |
| FR (1) | FR2134658B1 (enExample) |
| GB (1) | GB1385086A (enExample) |
| HU (1) | HU166989B (enExample) |
| IL (1) | IL39181A (enExample) |
| NL (1) | NL178258C (enExample) |
| NO (1) | NO137178C (enExample) |
| PL (1) | PL86966B1 (enExample) |
| RO (1) | RO64387A (enExample) |
| SE (1) | SE378066B (enExample) |
| SU (1) | SU508162A3 (enExample) |
| YU (1) | YU36155B (enExample) |
| ZA (1) | ZA722243B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK140801B (da) * | 1975-01-15 | 1979-11-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af et stabilt langtidsvirkende insulinpræparat. |
| NL193099C (nl) * | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
| WO1988002633A1 (en) * | 1986-10-20 | 1988-04-21 | Novo Industri A/S | Protamine zinc insulin preparations |
| ES2053723T3 (es) * | 1987-02-25 | 1994-08-01 | Novo Nordisk As | Nuevos derivados de insulina. |
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| US6624141B1 (en) * | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| PH12011502708B1 (en) | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| BR112020002804A2 (pt) | 2017-08-24 | 2020-07-28 | Novo Nordisk A/S | composição farmacêutica líquida, e, kit |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
| CN122005837A (zh) * | 2023-08-07 | 2026-05-12 | 浙江大学 | 一种糖响应鱼精蛋白胰岛素及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5038E (fr) * | 1904-03-09 | 1905-12-02 | Georges Frederic Brade | Perfectionnements dans la fabrication des organes du métronome |
| GB889769A (en) * | 1957-07-18 | 1962-02-21 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form |
-
1971
- 1971-04-30 US US00139120A patent/US3758683A/en not_active Expired - Lifetime
-
1972
- 1972-04-04 ZA ZA722243A patent/ZA722243B/xx unknown
- 1972-04-10 IL IL39181A patent/IL39181A/en unknown
- 1972-04-17 FI FI721077A patent/FI49773C/fi active
- 1972-04-20 DD DD162448A patent/DD100708A5/xx unknown
- 1972-04-21 DE DE2219635A patent/DE2219635C3/de not_active Expired
- 1972-04-24 NO NO1423/72A patent/NO137178C/no unknown
- 1972-04-26 SU SU1778186A patent/SU508162A3/ru active
- 1972-04-26 BE BE782651A patent/BE782651A/xx not_active IP Right Cessation
- 1972-04-26 JP JP4209072A patent/JPS5735185B1/ja active Pending
- 1972-04-27 DK DK209472A patent/DK131760C/da not_active IP Right Cessation
- 1972-04-27 PL PL1972155003A patent/PL86966B1/pl unknown
- 1972-04-27 ES ES402176A patent/ES402176A1/es not_active Expired
- 1972-04-28 CH CH633872A patent/CH566784A5/xx not_active IP Right Cessation
- 1972-04-28 CA CA140,826A patent/CA976085A/en not_active Expired
- 1972-04-28 NL NLAANVRAGE7205865,A patent/NL178258C/xx not_active IP Right Cessation
- 1972-04-28 HU HUEI419A patent/HU166989B/hu unknown
- 1972-04-28 GB GB1974172A patent/GB1385086A/en not_active Expired
- 1972-04-28 FR FR7215270A patent/FR2134658B1/fr not_active Expired
- 1972-04-28 YU YU1142/72A patent/YU36155B/xx unknown
- 1972-04-28 SE SE7205698A patent/SE378066B/xx unknown
- 1972-04-28 CS CS722923A patent/CS209458B2/cs unknown
- 1972-04-29 RO RO7270743A patent/RO64387A/ro unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL39181A0 (en) | 1972-06-28 |
| DK131760B (da) | 1975-09-01 |
| NO137178C (no) | 1978-01-18 |
| YU114272A (en) | 1981-06-30 |
| JPS5735185B1 (enExample) | 1982-07-27 |
| CA976085A (en) | 1975-10-14 |
| DE2219635C3 (de) | 1981-10-15 |
| US3758683A (en) | 1973-09-11 |
| ZA722243B (en) | 1973-11-28 |
| NO137178B (no) | 1977-10-10 |
| HU166989B (enExample) | 1975-07-28 |
| SU508162A3 (ru) | 1976-03-25 |
| NL7205865A (enExample) | 1972-11-01 |
| NL178258B (nl) | 1985-09-16 |
| RO64387A (fr) | 1979-07-15 |
| DE2219635A1 (de) | 1972-11-09 |
| FI49773B (enExample) | 1975-06-30 |
| DD100708A5 (enExample) | 1973-10-05 |
| FR2134658B1 (enExample) | 1975-10-17 |
| PL86966B1 (enExample) | 1976-06-30 |
| BE782651A (fr) | 1972-10-26 |
| FI49773C (fi) | 1975-10-10 |
| IL39181A (en) | 1974-09-10 |
| DK131760C (da) | 1976-02-02 |
| ES402176A1 (es) | 1975-03-01 |
| CH566784A5 (enExample) | 1975-09-30 |
| YU36155B (en) | 1982-02-25 |
| NL178258C (nl) | 1986-02-17 |
| SE378066B (enExample) | 1975-08-18 |
| DE2219635B2 (de) | 1980-11-27 |
| FR2134658A1 (enExample) | 1972-12-08 |
| CS209458B2 (en) | 1981-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES402176A1 (es) | Un procedimiento para preparar un complejo de sal de insu- lina y protamina. | |
| GB1413669A (en) | Preparation of catalysts from zeolite l | |
| GB1466153A (en) | Treatment of diarrhea in mammals | |
| GB1471482A (en) | Heparing salts | |
| GB1427243A (en) | Process for the preparation of manganese ethylene bisdithio carbamate products and fungicidal compositions containing the products prepared in this way | |
| GB1256968A (enExample) | ||
| GB1422193A (en) | Pharmaceutical compositions | |
| GB748024A (en) | Improved therapeutic preparations of iron | |
| GB1189880A (en) | An Improved Tobacco Product | |
| GB1451352A (en) | Method of suppressing mildew using a composition containing an alkanoic acid salt | |
| GB1415453A (en) | Composition and process for producing aquarium water having improved properties | |
| GB1170318A (en) | Improvements in or relating to Inhibiting the Discolouration of Egg White | |
| GB1382008A (en) | Fungicidal and/or bacterial composition and method | |
| GB929554A (en) | Process for pickling ham | |
| GB1161970A (en) | Improvements in or relating to Compositions Containing Choline Chloride | |
| GB1313164A (en) | Blood plasma substitute | |
| GB889769A (en) | Slowly acting insulin preparation in crystalline form | |
| GB1348798A (en) | Process for the production of citric acid by submerged fermentation | |
| GB1342311A (en) | Process for the production of citric acid by submerged fer mentation | |
| GB1237309A (en) | Stabilising aqueous solutions of potassium persulphate | |
| GB1389406A (en) | Powdered alkali metal borogluco-heptonates | |
| GB782715A (en) | Process for the preparation of lead azide | |
| GB1382609A (en) | Preparation of eburnamine alkaloid | |
| GB1392942A (en) | Process for the production of citric acid by submerged fermentation | |
| GB748857A (en) | Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |